logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Veverimer for metabolic acidosis associated with chronic kidney disease

< Back

Veverimer for metabolic acidosis associated with chronic kidney disease

Drugs

Endocrine, Nutritional and Metabolic

May 2020


Veverimer is currently in clinical development for the treatment of metabolic acidosis associated with chronic kidney disease (CKD). One of the roles of the kidneys is to remove excess acid from the blood and excrete the acid in urine. In CKD, the kidneys do not function as well as they should so they cannot remove acid adequately. This results in a build-up of acid in the blood that can cause symptoms such as confusion, fast heartbeat, headache, loss of appetite, vomiting and feeling weak or tired. Metabolic acidosis in CKD can result in increased bone loss, progression of kidney disease, muscle loss and endocrine disorders such as diabetes.

Veverimer is given as an oral suspension and it works by binding to hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the faeces. Preliminary results from early studies have demonstrated that veverimer is efficacious and safe. If licensed, veverimer could offer an additional treatment option for patients with metabolic acidosis associated with CKD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts